Cargando…

Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study

BACKGROUND: Type 2 diabetes (T2D) is strongly associated with cardiovascular risk and requires medications that improve glycemic control and other cardiovascular risk factors. The authors aimed to assess the relative effectiveness of pioglitazone (Pio), metformin (Met) and any sulfonylurea (SU) comb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodríguez, Ángel, Reviriego, Jesús, Karamanos, Vasilios, del Cañizo, Francisco J, Vlachogiannis, Nikolaos, Drossinos, Vangelis
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042924/ https://www.ncbi.nlm.nih.gov/pubmed/21314919 http://dx.doi.org/10.1186/1475-2840-10-18

Ejemplares similares

Teriparatide use during an economic crisis: baseline data from the Greek cohort of the Extended Forsteo Observational Study (ExFOS)
por: Aloumanis, Kyriakos, et al.
Publicado: (2015)

Pioglitazone for primary stroke prevention in Asian patients with type 2 diabetes and cardiovascular risk factors: a retrospective study
por: Hung, Yi-Chih, et al.
Publicado: (2020)

Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort study
por: Liu, Chi-Hung, et al.
Publicado: (2020)

Lack of effects of pioglitazone on cardiac function in patients with type 2 diabetes and evidence of left ventricular diastolic dysfunction: a tissue doppler imaging study
por: Naka, Katerina K, et al.
Publicado: (2010)

Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of Pioglitazone, Metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study
por: Hanefeld, Markolf, et al.
Publicado: (2011)

Use of pioglitazone in the treatment of diabetes: effect on cardiovascular risk
por: Zou, Cong, et al.
Publicado: (2013)

Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case–control study
por: Woo, Min-Hee, et al.
Publicado: (2019)

Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes
por: Dorkhan, Mozhgan, et al.
Publicado: (2009)

Pioglitazone stabilizes atherosclerotic plaque by regulating the Th17/Treg balance in AMPK-dependent mechanisms
por: Tian, Yuling, et al.
Publicado: (2017)

Cohort Study of Pioglitazone and Cancer Incidence in Patients With Diabetes
por: Ferrara, Assiamira, et al.
Publicado: (2011)

Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report
por: Suzuki, Hirofumi, et al.
Publicado: (2013)

Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study
por: Juurlink, David N, et al.
Publicado: (2009)

The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety
por: Leonard, Charles E., et al.
Publicado: (2020)

Effect of Pioglitazone on Perihematomal Edema in Intracerebral Hemorrhage Mouse Model by Regulating NLRP3 Expression and Energy Metabolism
por: Kim, Hoon, et al.
Publicado: (2020)

Pioglitazone enhances collateral blood flow in ischemic hindlimb of diabetic mice through an Akt-dependent VEGF-mediated mechanism, regardless of PPARγ stimulation
por: Biscetti, Federico, et al.
Publicado: (2009)

Arsenic: A Perspective on Its Effect on Pioglitazone Bioavailability
por: Terrones-Gurrola, María Cruz del Rocío, et al.
Publicado: (2023)

Relationships between obesity, glycemic control, and cardiovascular risk factors: a pooled analysis of cross-sectional data from Spanish patients with type 2 diabetes in the preinsulin stage
por: Vázquez, Luis A, et al.
Publicado: (2014)

Cardiovascular events and all-cause mortality in a cohort of 57,946 patients with type 2 diabetes: associations with renal function and cardiovascular risk factors
por: Cea Soriano, Lucia, et al.
Publicado: (2015)

Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective
por: Kanhai, Anish A., et al.
Publicado: (2020)

Impact of diabetes duration and degree of carotid artery stenosis on major adverse cardiovascular events: a single-center, retrospective, observational cohort study
por: Noh, Minsu, et al.
Publicado: (2017)

Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study
por: Jin, Jing-Lu, et al.
Publicado: (2020)

Alogliptin in combination with metformin and pioglitazone for the treatment of type 2 diabetes mellitus
por: Holland, Daniel Q, et al.
Publicado: (2014)

Pioglitazone use associated with reduced risk of the first attack of ischemic stroke in patients with newly onset type 2 diabetes: a nationwide nested case–control study
por: Ha, Junghee, et al.
Publicado: (2021)

Lipoprotein (a) predicts recurrent worse outcomes in type 2 diabetes mellitus patients with prior cardiovascular events: a prospective, observational cohort study
por: Zhang, Yan, et al.
Publicado: (2020)

Effect of the Greek Solutions for Wellness weight management program on quality of life and associated factors in patients with a psychiatric disorder receiving psychotropic medication
por: Psarra, Vassiliki, et al.
Publicado: (2010)

Pioglitazone strengthen therapeutic effect of adipose-derived regenerative cells against ischemic cardiomyopathy through enhanced expression of adiponectin and modulation of macrophage phenotype
por: Mori, Daisuke, et al.
Publicado: (2019)

Comparison of dipeptidyl peptidase-4 inhibitors and pioglitazone combination therapy versus pioglitazone monotherapy in type 2 diabetes: A system review and meta-analysis
por: Wang, Ben, et al.
Publicado: (2018)

Risk factors associated with metabolic syndrome in type 2 diabetes mellitus patients according to World Health Organization, Third Report National Cholesterol Education Program, and International Diabetes Federation definitions
por: Rodríguez, Angel, et al.
Publicado: (2010)

Association of circulating PCSK9 concentration with cardiovascular metabolic markers and outcomes in stable coronary artery disease patients with or without diabetes: a prospective, observational cohort study
por: Peng, Jia, et al.
Publicado: (2020)

Efficacy and safety of pioglitazone in type 2 diabetes in the Indian patients: Results of an observational study
por: Balaji, Vijayam
Publicado: (2013)

Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study
por: Bromage, Daniel I., et al.
Publicado: (2019)

The TOSCA.IT Trial: A Study Designed to Evaluate the Effect of Pioglitazone Versus Sulfonylureas on Cardiovascular Disease in Type 2 Diabetes
por: Vaccaro, Olga, et al.
Publicado: (2012)

Glitazones and alpha-glucosidase inhibitors as the second-line oral anti-diabetic agents added to metformin reduce cardiovascular risk in Type 2 diabetes patients: a nationwide cohort observational study
por: Chan, Cheng-Wei, et al.
Publicado: (2018)

Differential Cardiovascular Outcomes after Dipeptidyl Peptidase-4 Inhibitor, Sulfonylurea, and Pioglitazone Therapy, All in Combination with Metformin, for Type 2 Diabetes: A Population-Based Cohort Study
por: Seong, Jong-Mi, et al.
Publicado: (2015)

Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study
por: Kim, Kyoung Jin, et al.
Publicado: (2019)

Cardiovascular disease risk profile and microvascular complications of diabetes: comparison of Indigenous cohorts with diabetes in Australia and Canada
por: Maple-Brown, Louise J, et al.
Publicado: (2012)

Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study
por: Gupta, Sunil, et al.
Publicado: (2015)

Pioglitazone: Indian perspective
por: Shukla, Rishi, et al.
Publicado: (2011)

Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and Bærum Cardiovascular Diabetes (ABCD) cohort study
por: Ofstad, Anne Pernille, et al.
Publicado: (2013)

Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
por: Triplitt, Curtis, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_7ul5mivfq7jhi88huv91o69qsu